Form 4: Immunome CEO Acquires Shares in Open Market Transactions

Immunome's CEO, Clay B. Siegall, acquired a total of 100,000 shares of common stock in two open market transactions.

Summary

• Immunome's CEO, Clay B. Siegall, purchased 66,057 shares of common stock on November 21, 2024, at a weighted average price of $9.5412 per share.
• The price range for the November 21st transaction was between $9.41 and $9.68 per share.
• On November 22, 2024, the CEO acquired an additional 33,943 shares at a weighted average price of $9.7787 per share.
• The price range for the November 22nd transaction was between $9.41 and $9.90 per share.
• Following these transactions, Mr. Siegall directly owns 519,636 shares of Immunome common stock.

Sentiment

Score: 8

Explanation: The document reflects a positive sentiment due to the CEO's significant open market purchases, indicating confidence in the company's prospects.

Positives

• The CEO's open market purchases demonstrate confidence in the company's future prospects.
• The increased shareholding by the CEO aligns his interests with those of other shareholders.

Industry Context

Insider buying is often seen as a positive signal in the biotech industry, suggesting management's belief in the company's potential.

Comparison to Industry Standards

• Open market purchases by CEOs are a common occurrence in publicly traded companies, particularly in the biotech sector.
• The size of the purchase, 100,000 shares, is significant and indicates a strong level of confidence from the CEO.
• Comparable companies often see similar insider transactions, with the impact on share price varying based on market conditions and company performance.

Stakeholder Impact

• The CEO's share purchases may positively impact shareholder confidence.
• The increased shareholding by the CEO aligns his interests with those of other shareholders.

Key Dates

Keywords

Immunome, IMNM, CEO, Clay Siegall, share purchase, insider trading, open market, common stock